KemPharm is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.
As Executive Vice President of Research and Development, Dr. Guenther leads KemPharm’s research team and plays a central role in the advancement of the company’s pipeline of NME prodrugs and the development of new products that utilize KemPharm’s proprietary LAT™ discovery technology to improve one or more of the attributes of approved drugs.
Prior to joining KemPharm, Dr. Guenther served as a research scientist for New River Pharmaceuticals, where he was part of the development team for Vyvanse®. He is an inventor on a number of patents and patent applications and author of several research papers.
Dr. Guenther received his Ph.D. degree from the University of Iowa.